Drug Cocktail Promising for Breast Cancer
Posted on: Wednesday, 5 April 2006, 00:00 CDT
Texas researchers say breast cancer patients with HER2-positive tumors who do not respond to Herceptin may respond to a cocktail that includes the drug.
The cocktail shows promise in experimental work with mice and cell cultures.
Dr. Dihua Yu and her colleagues at the University of Texas M.D. Anderson Cancer Center found that patients who do not respond to Herceptin have low levels of a protein that is a powerful tumor suppressor gene in their cancers. Because the protein, PTEN, works by blocking PI3K, a protein that encourages growth, she decided to try an experimental PI3K inhibitor.
If this drug cocktail shows benefit, we hope to be able to identify those patients who won't respond to Herceptin before they start the treatment, and offer them a new and beneficial drug combination, Yu said. Patients who don't respond to Herceptin have worrisome outcomes, so we hope this strategy will help them.
Yu presents her research Wednesday at the annual meeting of the American Association for Cancer Research in Washington.
Source: United Press International
Related Articles
- First Patient Enrolled in Phase II Cancer Trial
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Platinum-Resistant Ovarian Cancer
- Experimental Drug Delays Breast Cancer
- Pain drug enhances lung cancer therapy: study
- EU allows Herceptin for early breast cancer: Roche
- Genentech Says Herceptin Could Cure Breast Cancer
- New Drug Hope for Cancer Sufferers
- Trial Shows New Drug May Help Cancer Patients Who Need Stem Cell Transplants
- Researchers Find Chemotherapy and Radiation Together May Be Better for Patients with Locally Advanced Lung Cancer
 |
 |
User Comments (0)
RSS Feeds